Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development
Marc J. Weintraub, Jessica Jeffrey, Charles S. Grob, Megan Ichinose, R. Lindsey Bergman, Ziva D. Cooper, David J. Miklowitz
Psychedelic Medicine September 6, 2023 DOI: 10.1089/psymed.2023.0018 via OpenAlex
Summary
AI-generated from the abstractA trial is planned to gather initial evidence on whether combining psilocybin with cognitive behavioral therapy is feasible, safe, acceptable, and has psychosocial benefits for people with major depressive disorder. The results will guide larger randomized trials to test this combined treatment's effects and explore how it might work through changes in thinking and emotion. The trial is registered at ClinicalTrials.gov with ID NCT05227612.
Study at a glance
| Characteristics | Trial protocol Randomized Peer reviewed |
|---|---|
| Population | Patients with depression and other mental health conditions |
| Intervention | Psilocybin-assisted cognitive behavioral therapy |
| Topics | Depression Psilocybin |
| Keywords | Cognitive behavioral therapy Psychotherapist Cognition |
| Citations | 4 |
| Registration | NCT05227612 |
| Key finding | The trial aims to provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of psilocybin-assisted cognitive behavioral therapy for depression. |
Abstract
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.